This product belongs to the quinolone antibacterial drug, which is the levorotatory form of ofloxacin. Its antibacterial activity is about twice that of ofloxacin. The main mechanism of action is to inhibit the activity of bacterial DNA gyrase and the replication of bacterial DNA. It has the characteristics of broad antibacterial spectrum and strong antibacterial effect, and has good antibacterial effect on most Enterobacteriaceae, some Staphylococci, Streptococcus pneumoniae, Haemophilus influenzae, Pseudomonas aeruginosa, Neisseria gonorrhoeae, Chlamydia, etc.

It has a strong effect on most Gram-positive and Gram-negative bacteria. It has a good antibacterial effect on Escherichia coli, Klebsiella pneumoniae, Proteus vulgaris, Shigella, and Salmonella, and its activity is slightly worse than kanamycin. It also has a good effect on some Staphylococci, gonococci, and meningococci. It has a weak effect on Streptococcus and Mycobacterium tuberculosis, and is ineffective against Pseudomonas aeruginosa and anaerobic bacteria. This product is cross-resistant with kanamycin. The results of the ototoxicity test showed that the hearing and cochlear pathological damage to guinea pigs was significantly lower than that of kanamycin and gentamicin.